(Q43226767)

16 November 2017

title

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues (English)

1 reference

16 November 2017

1 reference

1 reference

1 reference

20

1 reference

16 November 2017

6

Peter Buggisch

0 references

Heiner Wedemeyer

3

object named as

Heiner Wedemeyer

1 reference

16 November 2017

1

Florian van Bömmel

1 reference

16 November 2017

13

Ulrich Spengler

1 reference

16 November 2017

Robert A de Man

2

1 reference

16 November 2017

Katja Deterding

4

1 reference

16 November 2017

Jörg Petersen

5

1 reference

16 November 2017

Peter Buggisch

6

1 reference

16 November 2017

Andreas Erhardt

7

1 reference

16 November 2017

Dietrich Hüppe

8

1 reference

16 November 2017

Kerstin Stein

9

1 reference

16 November 2017

Jörg Trojan

10

1 reference

16 November 2017

Christoph Sarrazin

11

1 reference

16 November 2017

Wulf O Böcher

12

1 reference

16 November 2017

Hermann E Wasmuth

14

1 reference

16 November 2017

Jurrien G P Reinders

15

1 reference

16 November 2017

Bernd Möller

16

1 reference

16 November 2017

Peter Rhode

17

1 reference

16 November 2017

Heinz-Hubert Feucht

18

1 reference

16 November 2017

Bertram Wiedenmann

19

1 reference

16 November 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

16 November 2017

1 reference

16 November 2017

volume

51

1 reference

16 November 2017

issue

1

1 reference

16 November 2017

page(s)

73-80

1 reference

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

16 November 2017

cites work

1 reference

Acyclic nucleoside phosphonates: a key class of antiviral drugs

21 January 2018

1 reference

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

21 January 2018

1 reference

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

21 January 2018

1 reference

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants

21 January 2018

1 reference

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

21 January 2018

1 reference

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

21 January 2018

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains

21 January 2018

1 reference

Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.

21 January 2018

1 reference

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.23246

1 reference

16 November 2017

1 reference